External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

External broker reports(aggregated public sources)

Equity Bottom-Up

<p>Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab. Global footprint in +120 countries for biosimilars In generics, it is among the world's...</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab. Global footprint in +120 countries for biosimilars In generics, it is among the world's...Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon: Steady Q2 Numbers Amid Better Margins

External broker reports(aggregated public sources), Axis Direct

Axis Direct

<p>Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at rich valuations therefore we recommend HOLD with TP Rs 400.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at rich valuations therefore we recommend HOLD with TP Rs 400.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon: Price Erosion Impacts Growth in Biosimilars

<p>About the stock: Biocon is a leading biopharma company operating in biologics, small molecules, branded formulations and contract research.</p>
<ul>
<li>Revenue breakup: Biosimilars (37%), generics (31%), research services (29%)</li>
<li>Biosimilar/Insulin US pipeline- (Launched - Pegfilgrastim, Trastuzumab, Glargine; Aspart (expected in FY22E) and Bevacizumab (delayed)</li>
</ul>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

About the stock: Biocon is a leading biopharma company operating in biologics, small molecules, branded formulations and contract research.

Revenue breakup: Biosimilars (37%), generics (31%), research services (29%)
Biosimilar/Insulin US pipeline- (Launched - Pegfilgrastim, Trastuzumab, Glargine; Aspart (expected in FY22E) and Bevacizumab (delayed)

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Ltd (BIOS IN)

Biocon: Steady Q2 Numbers Amid Better Margins

Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals...

ICICI Securities Limited

Biocon: Price Erosion Impacts Growth in Biosimilars

Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Biocon: Steady Q2 Numbers Amid Better Margins

Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals...

ICICI Securities Limited

Biocon: Price Erosion Impacts Growth in Biosimilars

Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at...

Axis Direct

Biocon: Covid Related Challenges Drag Q1

Biocon is a leading biopharma company operating in biologics, small molecules, branded formulations and contract research.

ICICI Securities Limited